Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
(Source: Dermatology and Therapy)
Source: Dermatology and Therapy - October 30, 2023 Category: Dermatology Source Type: research
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
ConclusionIn this interim analysis, adults with moderate to severe PsO had higher long-term response rates at 2 years when treated with deucravacitinib versus adalimumab. Deucravacitinib response rates remained stable whereas adalimumab response rates declined in year 2.Graphical Abstract (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - October 29, 2023 Category: Dermatology Source Type: research
Thermal Therapy Modulation of the Psoriasis-Associated Skin and Gut Microbiome
ConclusionsChanges in lower-abundance microbial taxa presence and abundance could be the basis for the positive effect of thermal water treatment and drinking on the cutaneous and systemic symptomatology of psoriasis. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - October 29, 2023 Category: Dermatology Source Type: research
Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
AbstractChronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of comorbidities. Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. Here, the salient aspects of CSU and current status of data for omalizumab for patients with CSU are reviewed, with a focus ...
Source: Dermatology and Therapy - October 29, 2023 Category: Dermatology Source Type: research
Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries
ConclusionsThese data highlight the significant impact that AA can have beyond hair loss, especially for patients with severe AA. There was substantial physician –patient alignment on severity assessment. Higher physician-rated AA severity was associated with higher levels of patient-reported disease burden, including anxiety and depression, and work and activity impairment. These data may help inform appropriate treatment strategies. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - October 27, 2023 Category: Dermatology Source Type: research
The Diagnostic Workup, Screening, and Treatment Approaches for Patients with Delusional Infestation
This article serves as a guide for dermatologists, psychiatrists, and other clinicians as it reviews the workup and screening that should be considered when managing a patient with delusional infestation and subsequent treatment protocols once the diagnosis has been made. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - October 24, 2023 Category: Dermatology Source Type: research
Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
AbstractThis Summary of Research overviews the results of the VOLTAIRE-X study (NCT03210259), which looked at what happened when people with plaque psoriasis continually took the adalimumab reference product (adalimumab RP; known by the brand name Humira®) or switched three times between taking the adalimumab RP and BI 695501 (adalimumab-adbm, known by the brand name Cyltezo®), an adalimumab biosimilar. The VOLTAIRE-X study showed that the pharmacokinetics of adalimumab were similar in people who stayed continuously on adalimumab RP and people who switched between adalimumab RP and adalimumab-adbm. There were no differ...
Source: Dermatology and Therapy - October 24, 2023 Category: Dermatology Source Type: research
The Benefits of a Multimechanistic Antiaging Skin Technology
ConclusionThe serum combination of humectants, peptides, and antioxidants yielded excellent tolerability with visual and mechanistic skin improvement beginning at 1 week with cumulative continuing improvement through 24 weeks of use in terms of hydration, firmness, texture, radiance, and fine lines. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - October 20, 2023 Category: Dermatology Source Type: research
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
(Source: Dermatology and Therapy)
Source: Dermatology and Therapy - October 18, 2023 Category: Dermatology Source Type: research
Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 Trial
ConclusionIn the Chinese subgroup of the Effisayil 1 study, more patients receiving spesolimab experienced lesion clearance than those on placebo at week 1, with an acceptable safety profile that was consistent with the global study population.Trial RegistrationNCT03782792. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - October 16, 2023 Category: Dermatology Source Type: research
Application and Comparison of Dermoscopy and Reflectance Confocal Microscopy in the Target Treatment of Genital Lichen Sclerosus: A Single-Arm Prospective Study
ConclusionBoth dermoscopy and RCM can be useful and non-invasive adjuvant tools for the evaluation and therapeutic monitoring of GLS. We recommended white structureless areas under dermoscopy and inflammatory cells count under RCM as variables for dermatologic imaging evaluation for GLS. Baricitinib is effective and safe for GLS, while randomized controlled trials are warranted. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - October 15, 2023 Category: Dermatology Source Type: research
Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study
ConclusionsTrifarotene was effective and well tolerated in treating moderate-to-severe facial acne and reducing atrophic acne scars, with reduction of total atrophic scar count as early as week 2.Trial RegistrationClinicaltrials.gov NCT04856904. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - October 15, 2023 Category: Dermatology Source Type: research
